Proactive Investors - Run By Investors For Investors

Avacta's Alastair Smith updates on selection of cancer candidate to take into clinic

Avacta Group PLC's (LON:AVCT) Alastair Smith tells Proactive London's Andrew Scott they've selected the cancer drug candidate they'll be taking into first-in-human clinical trials.

It's an important step for the company as it means they remain on track to submit an investigational new drug/clinical trial application by the end of next year.

View full AVCT profile View Profile

Avacta Group PLC Timeline

CN Research
April 09 2019

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use